RIPK2 and pachyonychia congenita: As expected, the frequency of RIPK2 mRNA overexpression also increases with PC progression, rising from 0.8% in tumor-adjacent normal tissue to 45.4% in metastatic or castration-resistant PC (Fig. 1d and Supplementary Fig. 1d).